世界の固形腫瘍治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Solid Tumors Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z5376 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、125ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、固形腫瘍治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（小分子、生物製剤）、用途別市場規模（病院、診療所、学術研究所）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・固形腫瘍治療薬の市場動向 ・企業の競争状況、市場シェア ・固形腫瘍治療薬の種類別市場規模（小分子、生物製剤） ・固形腫瘍治療薬の用途別市場規模（病院、診療所、学術研究所） ・固形腫瘍治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・固形腫瘍治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・固形腫瘍治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・固形腫瘍治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・固形腫瘍治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Hoffmann-La Roche、Novartis、Celgene、Johnson & Johnson、Pfizer、BMS、Eli Lilly、GSK、Merck、Sanofi、AbbVie、AstraZeneca、Bayer、Biogen、Boehringer Ingelheim、Boston Biomedical、Daiichi Sankyo） ・結論

Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.
During 2017, the biologics segment dominated the market and accounted for close to 55% of the market share in terms of revenue. This segment consists of medicinal products extracted from biological sources such as human, animal, microorganisms, or they are manufactured using the latest, cutting-edge biotechnological processes. Biologics include products such as enzymes, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines.

Market Analysis and Insights: Global Solid Tumors Drugs Market
The global Solid Tumors Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Solid Tumors Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Solid Tumors Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Solid Tumors Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Solid Tumors Drugs market.

Global Solid Tumors Drugs Scope and Market Size
Solid Tumors Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Solid Tumors Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Small Molecules
Biologics

Segment by Application
Hospitals
Clinics
Academic and Research Institutes

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Hoffmann-La Roche
Novartis
Celgene
Johnson & Johnson
Pfizer
BMS
Eli Lilly
GSK
Merck
Johnson & Johnson
Pfizer
AstraZeneca
Bayer
Biogen
Boehringer Ingelheim

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Solid Tumors Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Small Molecules
1.2.3 Biologics
1.3 Market by Application
1.3.1 Global Solid Tumors Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Academic and Research Institutes
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Solid Tumors Drugs Market Perspective (2016-2027)
2.2 Solid Tumors Drugs Growth Trends by Regions
2.2.1 Solid Tumors Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Solid Tumors Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Solid Tumors Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Solid Tumors Drugs Industry Dynamic
2.3.1 Solid Tumors Drugs Market Trends
2.3.2 Solid Tumors Drugs Market Drivers
2.3.3 Solid Tumors Drugs Market Challenges
2.3.4 Solid Tumors Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Solid Tumors Drugs Players by Revenue
3.1.1 Global Top Solid Tumors Drugs Players by Revenue (2016-2021)
3.1.2 Global Solid Tumors Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Solid Tumors Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Solid Tumors Drugs Revenue
3.4 Global Solid Tumors Drugs Market Concentration Ratio
3.4.1 Global Solid Tumors Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Solid Tumors Drugs Revenue in 2020
3.5 Solid Tumors Drugs Key Players Head office and Area Served
3.6 Key Players Solid Tumors Drugs Product Solution and Service
3.7 Date of Enter into Solid Tumors Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Solid Tumors Drugs Breakdown Data by Type
4.1 Global Solid Tumors Drugs Historic Market Size by Type (2016-2021)
4.2 Global Solid Tumors Drugs Forecasted Market Size by Type (2022-2027)

5 Solid Tumors Drugs Breakdown Data by Application
5.1 Global Solid Tumors Drugs Historic Market Size by Application (2016-2021)
5.2 Global Solid Tumors Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Solid Tumors Drugs Market Size (2016-2027)
6.2 North America Solid Tumors Drugs Market Size by Type
6.2.1 North America Solid Tumors Drugs Market Size by Type (2016-2021)
6.2.2 North America Solid Tumors Drugs Market Size by Type (2022-2027)
6.2.3 North America Solid Tumors Drugs Market Size by Type (2016-2027)
6.3 North America Solid Tumors Drugs Market Size by Application
6.3.1 North America Solid Tumors Drugs Market Size by Application (2016-2021)
6.3.2 North America Solid Tumors Drugs Market Size by Application (2022-2027)
6.3.3 North America Solid Tumors Drugs Market Size by Application (2016-2027)
6.4 North America Solid Tumors Drugs Market Size by Country
6.4.1 North America Solid Tumors Drugs Market Size by Country (2016-2021)
6.4.2 North America Solid Tumors Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Solid Tumors Drugs Market Size (2016-2027)
7.2 Europe Solid Tumors Drugs Market Size by Type
7.2.1 Europe Solid Tumors Drugs Market Size by Type (2016-2021)
7.2.2 Europe Solid Tumors Drugs Market Size by Type (2022-2027)
7.2.3 Europe Solid Tumors Drugs Market Size by Type (2016-2027)
7.3 Europe Solid Tumors Drugs Market Size by Application
7.3.1 Europe Solid Tumors Drugs Market Size by Application (2016-2021)
7.3.2 Europe Solid Tumors Drugs Market Size by Application (2022-2027)
7.3.3 Europe Solid Tumors Drugs Market Size by Application (2016-2027)
7.4 Europe Solid Tumors Drugs Market Size by Country
7.4.1 Europe Solid Tumors Drugs Market Size by Country (2016-2021)
7.4.2 Europe Solid Tumors Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Solid Tumors Drugs Market Size (2016-2027)
8.2 Asia-Pacific Solid Tumors Drugs Market Size by Type
8.2.1 Asia-Pacific Solid Tumors Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Solid Tumors Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Solid Tumors Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Solid Tumors Drugs Market Size by Application
8.3.1 Asia-Pacific Solid Tumors Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Solid Tumors Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Solid Tumors Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Solid Tumors Drugs Market Size by Region
8.4.1 Asia-Pacific Solid Tumors Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Solid Tumors Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Solid Tumors Drugs Market Size (2016-2027)
9.2 Latin America Solid Tumors Drugs Market Size by Type
9.2.1 Latin America Solid Tumors Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Solid Tumors Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Solid Tumors Drugs Market Size by Type (2016-2027)
9.3 Latin America Solid Tumors Drugs Market Size by Application
9.3.1 Latin America Solid Tumors Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Solid Tumors Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Solid Tumors Drugs Market Size by Application (2016-2027)
9.4 Latin America Solid Tumors Drugs Market Size by Country
9.4.1 Latin America Solid Tumors Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Solid Tumors Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Solid Tumors Drugs Market Size (2016-2027)
10.2 Middle East & Africa Solid Tumors Drugs Market Size by Type
10.2.1 Middle East & Africa Solid Tumors Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Solid Tumors Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Solid Tumors Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Solid Tumors Drugs Market Size by Application
10.3.1 Middle East & Africa Solid Tumors Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Solid Tumors Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Solid Tumors Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Solid Tumors Drugs Market Size by Country
10.4.1 Middle East & Africa Solid Tumors Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Solid Tumors Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Hoffmann-La Roche
11.1.1 Hoffmann-La Roche Company Details
11.1.2 Hoffmann-La Roche Business Overview
11.1.3 Hoffmann-La Roche Solid Tumors Drugs Introduction
11.1.4 Hoffmann-La Roche Revenue in Solid Tumors Drugs Business (2016-2021)
11.1.5 Hoffmann-La Roche Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Solid Tumors Drugs Introduction
11.2.4 Novartis Revenue in Solid Tumors Drugs Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Celgene
11.3.1 Celgene Company Details
11.3.2 Celgene Business Overview
11.3.3 Celgene Solid Tumors Drugs Introduction
11.3.4 Celgene Revenue in Solid Tumors Drugs Business (2016-2021)
11.3.5 Celgene Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Solid Tumors Drugs Introduction
11.4.4 Johnson & Johnson Revenue in Solid Tumors Drugs Business (2016-2021)
11.4.5 Johnson & Johnson Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Solid Tumors Drugs Introduction
11.5.4 Pfizer Revenue in Solid Tumors Drugs Business (2016-2021)
11.5.5 Pfizer Recent Development
11.6 BMS
11.6.1 BMS Company Details
11.6.2 BMS Business Overview
11.6.3 BMS Solid Tumors Drugs Introduction
11.6.4 BMS Revenue in Solid Tumors Drugs Business (2016-2021)
11.6.5 BMS Recent Development
11.7 Eli Lilly
11.7.1 Eli Lilly Company Details
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Solid Tumors Drugs Introduction
11.7.4 Eli Lilly Revenue in Solid Tumors Drugs Business (2016-2021)
11.7.5 Eli Lilly Recent Development
11.8 GSK
11.8.1 GSK Company Details
11.8.2 GSK Business Overview
11.8.3 GSK Solid Tumors Drugs Introduction
11.8.4 GSK Revenue in Solid Tumors Drugs Business (2016-2021)
11.8.5 GSK Recent Development
11.9 Merck
11.9.1 Merck Company Details
11.9.2 Merck Business Overview
11.9.3 Merck Solid Tumors Drugs Introduction
11.9.4 Merck Revenue in Solid Tumors Drugs Business (2016-2021)
11.9.5 Merck Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Details
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Solid Tumors Drugs Introduction
11.10.4 Sanofi Revenue in Solid Tumors Drugs Business (2016-2021)
11.10.5 Sanofi Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Details
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Solid Tumors Drugs Introduction
11.11.4 AbbVie Revenue in Solid Tumors Drugs Business (2016-2021)
11.11.5 AbbVie Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Details
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Solid Tumors Drugs Introduction
11.12.4 AstraZeneca Revenue in Solid Tumors Drugs Business (2016-2021)
11.12.5 AstraZeneca Recent Development
11.13 Bayer
11.13.1 Bayer Company Details
11.13.2 Bayer Business Overview
11.13.3 Bayer Solid Tumors Drugs Introduction
11.13.4 Bayer Revenue in Solid Tumors Drugs Business (2016-2021)
11.13.5 Bayer Recent Development
11.14 Biogen
11.14.1 Biogen Company Details
11.14.2 Biogen Business Overview
11.14.3 Biogen Solid Tumors Drugs Introduction
11.14.4 Biogen Revenue in Solid Tumors Drugs Business (2016-2021)
11.14.5 Biogen Recent Development
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Company Details
11.15.2 Boehringer Ingelheim Business Overview
11.15.3 Boehringer Ingelheim Solid Tumors Drugs Introduction
11.15.4 Boehringer Ingelheim Revenue in Solid Tumors Drugs Business (2016-2021)
11.15.5 Boehringer Ingelheim Recent Development
11.16 Boston Biomedical
11.16.1 Boston Biomedical Company Details
11.16.2 Boston Biomedical Business Overview
11.16.3 Boston Biomedical Solid Tumors Drugs Introduction
11.16.4 Boston Biomedical Revenue in Solid Tumors Drugs Business (2016-2021)
11.16.5 Boston Biomedical Recent Development
11.17 Daiichi Sankyo
11.17.1 Daiichi Sankyo Company Details
11.17.2 Daiichi Sankyo Business Overview
11.17.3 Daiichi Sankyo Solid Tumors Drugs Introduction
11.17.4 Daiichi Sankyo Revenue in Solid Tumors Drugs Business (2016-2021)
11.17.5 Daiichi Sankyo Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Solid Tumors Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Small Molecules
Table 3. Key Players of Biologics
Table 4. Global Solid Tumors Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Solid Tumors Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Solid Tumors Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Solid Tumors Drugs Market Share by Regions (2016-2021)
Table 8. Global Solid Tumors Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Solid Tumors Drugs Market Share by Regions (2022-2027)
Table 10. Solid Tumors Drugs Market Trends
Table 11. Solid Tumors Drugs Market Drivers
Table 12. Solid Tumors Drugs Market Challenges
Table 13. Solid Tumors Drugs Market Restraints
Table 14. Global Solid Tumors Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Solid Tumors Drugs Market Share by Players (2016-2021)
Table 16. Global Top Solid Tumors Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Solid Tumors Drugs as of 2020)
Table 17. Ranking of Global Top Solid Tumors Drugs Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Solid Tumors Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Solid Tumors Drugs Product Solution and Service
Table 21. Date of Enter into Solid Tumors Drugs Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Solid Tumors Drugs Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Solid Tumors Drugs Revenue Market Share by Type (2016-2021)
Table 25. Global Solid Tumors Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Solid Tumors Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Solid Tumors Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Solid Tumors Drugs Revenue Market Share by Application (2016-2021)
Table 29. Global Solid Tumors Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Solid Tumors Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Solid Tumors Drugs Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Solid Tumors Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Solid Tumors Drugs Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Solid Tumors Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Solid Tumors Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Solid Tumors Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Solid Tumors Drugs Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Solid Tumors Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Solid Tumors Drugs Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Solid Tumors Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Solid Tumors Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Solid Tumors Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Solid Tumors Drugs Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Solid Tumors Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Solid Tumors Drugs Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Solid Tumors Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Solid Tumors Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Solid Tumors Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Solid Tumors Drugs Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Solid Tumors Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Solid Tumors Drugs Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Solid Tumors Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Solid Tumors Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Solid Tumors Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Solid Tumors Drugs Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Solid Tumors Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Solid Tumors Drugs Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Solid Tumors Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Solid Tumors Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Solid Tumors Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 61. Hoffmann-La Roche Company Details
Table 62. Hoffmann-La Roche Business Overview
Table 63. Hoffmann-La Roche Solid Tumors Drugs Product
Table 64. Hoffmann-La Roche Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 65. Hoffmann-La Roche Recent Development
Table 66. Novartis Company Details
Table 67. Novartis Business Overview
Table 68. Novartis Solid Tumors Drugs Product
Table 69. Novartis Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 70. Novartis Recent Development
Table 71. Celgene Company Details
Table 72. Celgene Business Overview
Table 73. Celgene Solid Tumors Drugs Product
Table 74. Celgene Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 75. Celgene Recent Development
Table 76. Johnson & Johnson Company Details
Table 77. Johnson & Johnson Business Overview
Table 78. Johnson & Johnson Solid Tumors Drugs Product
Table 79. Johnson & Johnson Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 80. Johnson & Johnson Recent Development
Table 81. Pfizer Company Details
Table 82. Pfizer Business Overview
Table 83. Pfizer Solid Tumors Drugs Product
Table 84. Pfizer Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 85. Pfizer Recent Development
Table 86. BMS Company Details
Table 87. BMS Business Overview
Table 88. BMS Solid Tumors Drugs Product
Table 89. BMS Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 90. BMS Recent Development
Table 91. Eli Lilly Company Details
Table 92. Eli Lilly Business Overview
Table 93. Eli Lilly Solid Tumors Drugs Product
Table 94. Eli Lilly Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 95. Eli Lilly Recent Development
Table 96. GSK Company Details
Table 97. GSK Business Overview
Table 98. GSK Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 99. GSK Recent Development
Table 100. Merck Company Details
Table 101. Merck Business Overview
Table 102. Merck Solid Tumors Drugs Product
Table 103. Merck Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 104. Merck Recent Development
Table 105. Sanofi Company Details
Table 106. Sanofi Business Overview
Table 107. Sanofi Solid Tumors Drugs Product
Table 108. Sanofi Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 109. Sanofi Recent Development
Table 110. AbbVie Company Details
Table 111. AbbVie Business Overview
Table 112. AbbVie Solid Tumors Drugs Product
Table 113. AbbVie Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 114. AbbVie Recent Development
Table 115. AstraZeneca Company Details
Table 116. AstraZeneca Business Overview
Table 117. AstraZeneca Solid Tumors Drugs Product
Table 118. AstraZeneca Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 119. AstraZeneca Recent Development
Table 120. Bayer Company Details
Table 121. Bayer Business Overview
Table 122. Bayer Solid Tumors Drugs Product
Table 123. Bayer Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 124. Bayer Recent Development
Table 125. Biogen Company Details
Table 126. Biogen Business Overview
Table 127. Biogen Solid Tumors Drugs Product
Table 128. Biogen Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 129. Biogen Recent Development
Table 130. Boehringer Ingelheim Company Details
Table 131. Boehringer Ingelheim Business Overview
Table 132. Boehringer Ingelheim Solid Tumors Drugs Product
Table 133. Boehringer Ingelheim Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 134. Boehringer Ingelheim Recent Development
Table 135. Boston Biomedical Company Details
Table 136. Boston Biomedical Business Overview
Table 137. Boston Biomedical Solid Tumors Drugs Product
Table 138. Boston Biomedical Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 139. Boston Biomedical Recent Development
Table 140. Daiichi Sankyo Company Details
Table 141. Daiichi Sankyo Business Overview
Table 142. Daiichi Sankyo Solid Tumors Drugs Product
Table 143. Daiichi Sankyo Revenue in Solid Tumors Drugs Business (2016-2021) & (US$ Million)
Table 144. Daiichi Sankyo Recent Development
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Solid Tumors Drugs Market Share by Type: 2020 VS 2027
Figure 2. Small Molecules Features
Figure 3. Biologics Features
Figure 4. Global Solid Tumors Drugs Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Academic and Research Institutes Case Studies
Figure 8. Solid Tumors Drugs Report Years Considered
Figure 9. Global Solid Tumors Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Solid Tumors Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Solid Tumors Drugs Market Share by Regions: 2020 VS 2027
Figure 12. Global Solid Tumors Drugs Market Share by Regions (2022-2027)
Figure 13. Global Solid Tumors Drugs Market Share by Players in 2020
Figure 14. Global Top Solid Tumors Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Solid Tumors Drugs as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Solid Tumors Drugs Revenue in 2020
Figure 16. Global Solid Tumors Drugs Revenue Market Share by Type (2016-2021)
Figure 17. Global Solid Tumors Drugs Revenue Market Share by Type (2022-2027)
Figure 18. North America Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Solid Tumors Drugs Market Share by Type (2016-2027)
Figure 20. North America Solid Tumors Drugs Market Share by Application (2016-2027)
Figure 21. North America Solid Tumors Drugs Market Share by Country (2016-2027)
Figure 22. United States Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Solid Tumors Drugs Market Share by Type (2016-2027)
Figure 26. Europe Solid Tumors Drugs Market Share by Application (2016-2027)
Figure 27. Europe Solid Tumors Drugs Market Share by Country (2016-2027)
Figure 28. Germany Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Solid Tumors Drugs Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Solid Tumors Drugs Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Solid Tumors Drugs Market Share by Region (2016-2027)
Figure 38. China Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Solid Tumors Drugs Market Share by Type (2016-2027)
Figure 46. Latin America Solid Tumors Drugs Market Share by Application (2016-2027)
Figure 47. Latin America Solid Tumors Drugs Market Share by Country (2016-2027)
Figure 48. Mexico Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Solid Tumors Drugs Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Solid Tumors Drugs Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Solid Tumors Drugs Market Share by Country (2016-2027)
Figure 54. Turkey Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Solid Tumors Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Hoffmann-La Roche Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 58. Novartis Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 59. Celgene Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 60. Johnson & Johnson Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 61. Pfizer Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 62. BMS Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 63. Eli Lilly Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 64. GSK Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 65. Merck Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 66. Sanofi Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 67. AbbVie Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 68. AstraZeneca Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 69. Bayer Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 70. Biogen Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 71. Boehringer Ingelheim Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 72. Boston Biomedical Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 73. Daiichi Sankyo Revenue Growth Rate in Solid Tumors Drugs Business (2016-2021)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed

---